This article is more than 5 years old. Information may no longer be current.
Risk factors at middle age adversely affect brain size, function later in life
Debette S. Neurology. 2011;77:461-468.
Click Here to Manage Email Alerts
Diabetes, high BP, smoking and being overweight during middle age may have severe consequences on brain aging and cognition a decade later, new study results suggested.
“These factors appeared to cause the brain to lose volume, to develop lesions secondary to presumed vascular injury, and also appeared to affect its ability to plan and make decisions as quickly as 10 years later. A different pattern of association was observed for each of the factors,” Charles DeCarli, MD, study researcher with the University of California at Davis in Sacramento, said in a press release.
DeCarli and researchers looked at 1,352 participants (mean age, 54 years) without dementia from the Framingham Offspring Study to determine the association between midlife vascular risk factors and change in MRI markers of brain injury and cognitive function 10 years later.
They reported that hypertension was associated with accelerated white matter hyperintensity volume (P<.001), one of the MRI markers, and a decline in executive function (P=.012), whereas diabetes correlated with a marked increase in temporal horn volume (P=.012), a marker for accelerated hippocampal atrophy. Smoking also correlated with a rise in temporal horn volume (P=.012), while additionally proving detrimental to both total brain volume (P=.025) and extensive change in white matter hyperintensity volume (P=.021).
|
|
Furthermore, obesity was a predictor of a top quartile change in executive function (P=.035), whereas increasing waist-to-hip ratio led to a decline in total brain volume (P=.021).
“Our findings provide evidence that identifying these risk factors early in people of middle age could be useful in screening people for at-risk dementia and encouraging people to make changes to their lifestyle before it’s too late,” DeCarli said.
Disclosure: Dr. DeCarli serves as a consultant for Takeda Pharmaceutical Company Limited and Avanir Pharmaceuticals; receives research support from Merck Serono and the NIH; and is the editor-in-chief of Alzheimer Disease and Associated Disorders.
 |
Follow CardiologyToday.com on Twitter. |